Finland· FI-REL-REL59068
EVUSHELD
A tixagevimab und cilgavimab product containing tixagevimab + cilgavimab, registered in Finland by AstraZeneca AB. The same ATC class is registered in 3 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Tixagevimab und cilgavimab is registered in 3 of 19 countries.
Countries holding a registration under ATC J06BD03 (tixagevimab und cilgavimab), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 2 of them publish a price we can compare per daily dose
Tixagevimab und cilgavimab · ATC J06BD03
3 / 19 countries
- Belgiumprice
- Finlandprice
- Ireland
The record
At a glance
Fimea (Finland)- Active substance
- Tixagevimab + Cilgavimab
- Manufacturer
- AstraZeneca AB
- Country
- Finland (FI)
- ATC code
- J06BD03
- ATC class
- Tixagevimab und Cilgavimab
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tixagevimab und cilgavimab in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5ecda751-54cf-4287-8a86-f4e13a5085af GET /v1/drugs/5ecda751-54cf-4287-8a86-f4e13a5085af?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "injektioneste, liuos",
"route": "Lihakseen",
"ddd_unit": null,
"strength": "150 mg + 150 mg",
"atc_label": "tiksagevimabi ja silgavimabi",
"ma_number": null,
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": "EU/1/22/1651/001",
"fimea_rel_id": "REL59068",
"authorised_at": "2022-03-25"
}See everything about tixagevimab und cilgavimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.